[20200318]LSB10422_2019冠状病毒疾病医疗对策：知识产权和可承受性.pdf

CRS Legal Sidebar Prepared for Members and Committees of Congress Legal SidebarLegal Sidebari i COVID-19 Medical Countermeasures: Intellectual Property and Affordability March 18, 2020 Federal agencies and private industry have begun efforts to develop and test medical countermeasures (such as antiviral treatments and vaccines) to combat COVID-19, the disease caused by the novel coronavirus SARS-CoV-2. For example, Gilead Sciences has begun clinical trials, both in China and in the United States, to test whether its experimental antiviral drug remdesivir is safe and effective against COVID-19. In February 20202, the Biomedical Advanced Research and Development Authority (BARDA), a division of the Department of Health and Human Services (HHS), entered into agreements with two pharmaceutical companiesJohnson & Johnson and Sanofito develop vaccines for COVID-19. BARDA has also partnered with Regeneron Pharmaceuticals to develop a monoclonal antibody treatment for COVID-19. (See this CRS report for further detail on these and other potential countermeasures against COVID-19.) Members of Congress have raised concerns about whether these medical countermeasures, if shown to be safe and e